Jefferies Group LLC Tg Therapeutics, Inc. Call Options Transaction History

Jefferies Group LLC

10 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q2 2022 Aug 15, 2022	SELL	$3.74 - $10.66 $284,240 - $810,160	-76,000 Closed	0 $0
Q1 2022 Sep 21, 2023	BUY	$7.81 - $20.45 $523,270 - $1.37 Million	67,000 Added 744.44%	76,000 $722,000
Q1 2022 May 16, 2022	BUY	$7.81 - $20.45 $593,560 - $1.55 Million	76,000 New	76,000 $723,000
Q3 2021 Nov 15, 2021	SELL	$21.78 - $40.45 $196,020 - $364,050	-9,000 Closed	0 $0
Q2 2021 Sep 21, 2023	BUY	$32.5 - $48.96 $292,500 - $440,640	9,000 New	9,000 $349,000
Q2 2021 Aug 20, 2021	SELL	$32.5 - $48.96 $29 Million - $43.6 Million	-891,000 Reduced 99.0%	9,000 $349,000
Q2 2021 Aug 16, 2021	BUY	$32.5 - $48.96 $29.3 Million - $44.1 Million	900,000 New	900,000 $349,000
Q4 2019 Feb 13, 2020	SELL	$5.1 - $11.2 $866,999 - $1.9 Million	-170,000 Closed	0 $0
Q3 2019 Nov 13, 2019	BUY	$5.38 - $8.99 $237,258 - $396,459	44,100 Added 35.03%	170,000 $955,000
Q2 2018 Aug 14, 2018	BUY	$12.5 - $15.0 $1.57 Million - $1.89 Million	125,900 New	125,900 $1.66 Million

345

87.6M

2.35M

1.7M

Ticker TGTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 145,274,000
Market Cap $4.86B
Description
TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its therapeutic product candidates include Ublituximab, an investigational glycoengineered monoclonal antibody for the treatment of B-cell non-hod...

Get notified when there are updates to the investment portfolio of Jefferies Group LLC, based on Form 13F filings with the SEC.

Stay updated on Jefferies Group LLC with notifications on news.